Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)

PHASE3CompletedINTERVENTIONAL
Enrollment

637

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

April 8, 2020

Study Completion Date

April 8, 2020

Conditions
Secondary HyperparathyroidismChronic Kidney Disease
Interventions
DRUG

Etelcalcetide

Administered intravenously three times per week.

DRUG

Cinacalcet

Cinacalcet administered orally once a day.

Trial Locations (90)

10002

Research Site, Taipei

10449

Research Site, Taipei

10990

Research Site, George Town

11031

Research Site, Taipei

11101

Research Site, Taipei

20401

Research Site, Keelung

23561

Research Site, New Taipei City

30450

Research Site, Ipoh

33305

Research Site, Taoyuan District

40201

Research Site, Taichung

40705

Research Site, Taichung

50006

Research Site, Changhua

68100

Research Site, Batu Caves

70403

Research Site, Tainan City

71004

Research Site, Tainan City

83301

Research Site, Kaohsiung City

93586

Research Site, Kuching

100034

Research Site, Beijing

110004

Research Site, Shenyang

110022

Research Site, Shenyang

116001

Research Site, Dalian

116011

Research Site, Dalian

116027

Research Site, Dalian

130021

Research Site, Changchun

130041

Research Site, Changchun

200072

Research Site, Shanghai

200090

Research Site, Shanghai

200127

Research Site, Shanghai

200240

Research Site, Shanghai

210009

Research Site, Nanjing

210029

Research Site, Nanjing

213003

Research Site, Changzhou

214023

Research Site, Wuxi

266005

Research Site, Qingdao

300052

Research Site, Tianjin

300121

Research Site, Tianjin

310003

Research Site, Hangzhou

310009

Research Site, Hangzhou

410008

Research Site, Changsha

410011

Research Site, Changsha

430030

Research Site, Wuhan

430034

Research Site, Wuhan

430060

Research Site, Wuhan

450003

Research Site, Zhengzhou

450052

Research Site, Zhengzhou

510080

Research Site, Guangzhou

510120

Research Site, Guangzhou

510150

Research Site, Guangzhou

510180

Research Site, Guangzhou

510630

Research Site, Guangzhou

518035

Research Site, Shenzhen

524001

Research Site, Zhanjiang

530021

Research Site, Nanning

530022

Research Site, Nanning

570001

Research Site, Mysuru

590010

Research Site, Belagavi

610041

Research Site, Chengdu

610072

Research Site, Chengdu

710004

Research Site, Xi'an

730000

Research Site, Lanzhou

830054

Research Site, Ürümqi

030001

Research Site, Taiyuan

Unknown

Research Site, Hong Kong

Research Site, Kowloon

Research Site, New Territories

380 006

Research Site, Ahmedabad

387 001

Research Site, Nadiād

673 004

Research Site, Kozhikode

673 008

Research Site, Kozhikode

110 017

Research Site, New Delhi

110 025

Research Site, New Delhi

110 060

Research Site, New Delhi

110 070

Research Site, New Delhi

160 012

Research Site, Chandigarh

600 006

Research Site, Chennai

226 014

Research Site, Lucknow

248 001

Research Site, Dehradun

442 004

Research Site, Wardha

602-715

Research Site, Busan

602-739

Research Site, Busan

700-721

Research Site, Daegu

730-728

Research Site, Gumi-si, Gyeongsangbuk-do

471-701

Research Site, Guri-si, Gyeonggi-do

130-872

Research Site, Seoul

133-817

Research Site, Seoul

134-727

Research Site, Seoul

135-720

Research Site, Seoul

150-950

Research Site, Seoul

156-707

Research Site, Seoul

156-755

Research Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03299244 - Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) | Biotech Hunter | Biotech Hunter